"For all [drug] classes since the early 1980s, at least one follow-on drug* was synthesized, and at least one had initial pharmacological testing, prior to approval of the first-in-class drug."
"Nearly all of the follow-on drugs for classes where the first-in-class drug was approved in the 1990s were synthesized, had initial pharmacological testing, and were in clinical testing [...] before the first-in-class drug was approved."
"Development races better characterise new drug development than does a model of post hoc imitation."
"The drug industry’s shift away from random screening toward a more targeted rational drug design approach to drug discovery has increased the advantages obtained from connectedness to scientific networks, and so has increased the likelihood that a number of firms will be working on compounds in the same class at more or less the same time."






*Follow-on drug: drug entity with a similar chemical structure or the same mechanism of action as that of a drug already on the market.

«	page 1/2	»
	1